VEMLIDY is proven in robust global clinical trials1-5

Study design Renal safety parameters Viral suppression Impact on bone mineral density ALT normalization rates Adverse reactions Cirrhosis & fibrosis data*

*The data is not presented in the VEMLIDY label.

ALT=alanine aminotransferase.

Watch experts discuss treatment guidelines and algorithms

See how your patients could benefit from these treatment approaches

View now
 

Help your patients save on prescription costs

Eligible commercially insured patients can save with the VEMLIDY Co-pay Savings Program*

*For commercially insured eligible patients only. Restrictions apply. Subject to change; click “See the details” below for full terms and conditions. This is not health insurance. Only accepted at participating pharmacies.

See the details

VEMLIDY is recommended by global treatment guidelines and algorithms as a preferred first-line therapy for the treatment of chronic hepatitis B in adults with compensated liver disease7-11,a

AASLD 2025

SABA 2022

EASL 2025

China 2022

AATA 2018

Explore treatment guidelines/algorithms

AASLD=American Association for the Study of Liver Diseases; AATA=Asian American Treatment Algorithm; EASL=European Association for the Study of the Liver; SABA=Simplified Approach Hepatitis B Algorithm.

aOther recommended first-line nucleoside/nucleotide analogs are entecavir and tenofovir disoproxil fumarate (TDF).7-11

 

VEMLIDY offers convenient, patient-friendly dosing with a once-daily pill1

VEMLIDY is a 25-mg pill that’s 8 mm in diameter. Pill image not to scale.

Learn more
 

For your patients: Real VEMLIDY patients share their stories

Share their journeys with your patients, and download other available patient resources

See more

Patient compensated by Gilead.

References: 1. VEMLIDY Prescribing Information. Foster City, CA: Gilead Sciences, Inc.; March 2024. 2. Data on file. Gilead Sciences, Inc. 3. Buti M, Lim Y-S, Chan HLY, et al. Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials. Aliment Pharmacol Ther. 2024;60(11-12):1573-1586. doi:10.1111/apt.18278 4. Chan HLY, Fung S, Seto WK, et al; GS-US-320-0110 investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185-195. doi:10.1016/S2468-1253(16)30024-3 5. Chan HLY, Lim YS, Seto WKW, et al. 3-year efficacy and safety of tenofovir alafenamide compared with tenofovir disoproxil fumarate in HBeAg-negative and -positive patients with chronic hepatitis B. Poster presented at: AASLD 2018; November 9-13, 2018; San Francisco, CA. Poster 381. 6. Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68(4):672-681. doi:10.1016/j.jhep.2017.11.039 7. Ghany MG, Pan CQ, Lok AS, et al. AASLD IDSA Practice Guideline on treatment of chronic hepatitis B. Hepatology. 2026;83(4):974-997. doi:10.1097/HEP.0000000000001549 8. Dieterich D, Graham C, Wang S, et al. It is time for a simplified approach to hepatitis B elimination. Gastro Hep Adv. 2022;2(2):209-218. doi:10.1016/j.gastha.2022.10.004 9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502-583. doi:10.1016/j.jhep.2025.03.018 10. You H, Wang F, Li T, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11(6):1425-1442. doi:10.14218/JCTH.2023.00320 11. Tong MJ, Pan CQ, Han SB, et al. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther. 2018;47:1181-1200.